Document Detail


RhBMP-2 is superior to iliac crest bone graft for long fusions to the sacrum in adult spinal deformity: 4- to 14-year follow-up.
MedLine Citation:
PMID:  23392417     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
STUDY DESIGN: Matched cohort comparison.
OBJECTIVE: To compare the use of bone morphogenetic protein (BMP) or iliac crest bone graft (ICBG) on the long-term outcomes in patients undergoing long fusions to the sacrum for adult spinal deformity.
SUMMARY OF BACKGROUND DATA: No long-term studies beyond a 2-year follow-up have been performed comparing the use of BMP versus ICBG for fusion rates in long fusions to the sacrum in adult spinal deformity.
METHODS: A total of 63 consecutive patients, from 1997-2006, comprised of 31 patients in the BMP group and 32 patients in the ICBG group, operated on at a single institution with a minimum 4-year follow-up (4-14 yr) were analyzed. Inclusion criteria were ambulators who were candidates for long fusions (thoracic as the upper level) to the sacrum. Exclusion criteria were revisions, neuromuscular scoliosis, ankylosing spondylitis, and patients who had both BMP and ICBG used for fusion. Oswestry Disability Index and 3 domains of the Scoliosis Research Society score were used to assess outcomes.
RESULTS: The 2 groups were similar with respect to age, sex, smoking history, comorbidities, BMI, number of fusion levels and Cobb angles. Eight patients in the BMP group underwent a posterior only, whereas 23 underwent combined anterior and posterior (A/P) surgery. All 32 patients in the ICBG had A/P fusion. The average BMP level was 11.1 mg (3-36 mg). The rate pseudarthrosis was 6.4% (2/31) in the BMP and 28.1% (9/32) in the ICBG group (P = 0.04) using Fisher exact test and odds ratio = 5.67. The fusion rates for BMP group were 93.5% and 71.9% for the ICBG group. Oswestry Disability Indexes were similar between groups. However, the BMP group demonstrated superior sum composite Scoliosis Research Society scores in pain, self-image and function domains (P = 0.02).
CONCLUSION: BMP is superior to ICBG in achieving fusion in long constructs in adult deformity surgery. The rate of pseudarthrosis was significantly higher in the ICBG group than BMP group. The concentration and dosage of recombinant human bone morphogenetic protein 2 (rhBMP-2) used seems to have an effect on the rate of fusion and pseudarthrosis rate because no patient receiving more than 5 mg per level had apparent or detected pseudarthroses (n = 20/20).
LEVEL OF EVIDENCE: 3.
Authors:
Han Jo Kim; Jacob M Buchowski; Lukas P Zebala; Douglas D Dickson; Linda Koester; Keith H Bridwell
Related Documents :
18760147 - Use of and inhospital outcomes after early clopidogrel therapy in patients not undergoi...
1903167 - Intravenous recombinant tissue-type plasminogen activator (rt-pa) and urokinase (uk) in...
9164877 - Effect of continuous quality improvement analysis on the delivery of primary percutaneo...
20517957 - Comparison of door-to-balloon times for primary pci using transradial versus transfemor...
16902757 - Clinical and densitometric efficacy of the association of interferon alpha and pamidron...
19373427 - Long-term mortality and risk of stroke after transient ischemic attack: a hospital-base...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Spine     Volume:  38     ISSN:  1528-1159     ISO Abbreviation:  Spine     Publication Date:  2013 Jun 
Date Detail:
Created Date:  2013-06-13     Completed Date:  2014-01-13     Revised Date:  2014-07-31    
Medline Journal Info:
Nlm Unique ID:  7610646     Medline TA:  Spine (Phila Pa 1976)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1209-15     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Bone Morphogenetic Protein 2 / therapeutic use*
Bone Transplantation / adverse effects,  methods
Cohort Studies
Disability Evaluation
Follow-Up Studies
Humans
Ilium / transplantation*
Middle Aged
Pseudarthrosis / diagnosis,  etiology
Recombinant Proteins / therapeutic use
Sacrum / surgery*
Scoliosis / surgery
Spinal Fusion / adverse effects,  methods*
Spine / abnormalities,  radiography,  surgery*
Time Factors
Transforming Growth Factor beta / therapeutic use*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Bone Morphogenetic Protein 2; 0/Recombinant Proteins; 0/Transforming Growth Factor beta; 0/recombinant human bone morphogenetic protein-2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Ankylosing Spondylitis: A New Method for Calculating the Exact Angle Required for Spinal Osteotomy.
Next Document:  Development of the Lumbar Lordotic Curvature in Children From Age 2 to 20 Years.